Ake­bia shares MACEd as their PhI­II ane­mia drug fails on safe­ty, of­fer­ing ri­val Fi­bro­Gen a huge ad­van­tage

Ake­bia $AK­BA slammed di­rect­ly in­to an un­ex­pect­ed brick wall Thurs­day morn­ing, as the biotech re­port­ed a crit­i­cal fail­ure in its sec­ond Phase III study of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.